Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 258 of 6351
-
Can lowering phosphate save hearts in kidney failure?
Disease control Recruiting nowDuring end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high leve…
Sponsor: The University of Queensland • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug gilteritinib takes on standard therapy in FLT3 leukemia trial
Disease control CompletedEligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during in…
Phase 2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo attack on eye cancer that spreads to the liver
Disease control OngoingMelanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs. In this study a combination therapy with immunotherapy (ipilimumab with n…
Phase 1/2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Can targeted radiation slow prostate cancer that resists hormone therapy?
Disease control OngoingThe purpose of this randomized trial is to investigate the efficacy and toxicity of percutaneous high-dose radiotherapy in patients with oligometastases of hormone refractory prostate cancer. The effectiveness will be tested in comparison to an observation group, in which no furt…
Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Combining two drugs may tackle bladder cancer that resists standard therapy
Disease control OngoingThis study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG. The …
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody drug shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. …
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo may let CML patients pause treatment
Disease control OngoingThe investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a stable MR4.5 allowing cessation of imatinib treatment. The investigators proposal is to c…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Freeze and boost: new combo aims to stop breast cancer return
Disease control OngoingThe purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after ta…
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New cocktail aims to stall lung cancer progression
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with metastatic nonsquamous non-small cell lung cancer. …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 26, 2026 14:55 UTC
-
New hope for tough leukemias: experimental pill targets genetic weakness
Disease control Recruiting nowPhase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- an…
Phase 1/2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug cocktail aims to beat back stubborn leukemia
Disease control Recruiting nowThis study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" \[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)\] in the treatment of acute myeloid leukemia (AML) that has not responded well to standard …
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
High-Dose radiation may extend life for patients with a few cancer spots
Disease control OngoingStereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR…
Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug could simplify treatment for rare EGPA disease
Disease control OngoingThis is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug offer Long-Term relief for muscle weakness?
Disease control CompletedThe purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could a Half-Matched donor cure a rare immune disease?
Cure OngoingBackground: CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives: To see if it is safe …
Early phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
New drug shows promise for rare childhood cancers
Disease control OngoingThis phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking th…
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug aims to boost immunity in rare WHIM syndrome
Disease control CompletedThis study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of cir…
Phase 3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for stage IV breast cancer: adding surgery or radiation to targeted therapy
Disease control OngoingApproximately 3.5% to 6% of newly diagnosed breast cancer patients are stage IV metastatic. De novo metastatic breast cancer accounts for 20% to 25% of these cases. Despite a decrease in mortality in Europe and North America due to early detection and access to treatment, breast …
Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo aims to stop aggressive lymphoma in its tracks
Disease control OngoingThis phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of drugs used for treatment. Venetoclax may stop the growth of cancer cells by blocking …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for frail myeloma patients: targeted combo aims to control cancer with fewer side effects
Disease control OngoingThis is a Phase 3, randomized (study drug assigned by chance), open-label (participants and researchers are aware about the treatment, participants are receiving), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or pro…
Phase 3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC